Monograph Details
|
|
Immune System
> Immunization
|
|
DECAVAC |
| Manufacturer |
|
Sanofi Pasteur, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Td vaccine. |
| Generic Name |
|
Tetanus and diphtheria toxoids; aluminum adsorbed; susp for IM inj; contains thimerosal (trace). |
| Indications |
|
Tetanus and diphtheria immunization in patients ≥7yrs. |
| Adults and Children |
|
<7yrs: not recommended. ≥7yrs: Give IM in anterolateral thigh or deltoid. Previously unvaccinated: three 0.5mL doses at elected date, then 4–8 weeks after first dose, and 6–12 months after second dose. Give booster dose at 11–12 yrs of age if last dose of tetanus and diphtheria toxoid-containing vaccine was given ≥5yrs ago. Other: give booster every 10 years. Diphtheria and tetanus prophylaxis: see literature. |
| Precautions |
|
Defer in moderate or severe active respiratory or other febrile infection (may vaccinate if mild or minor illness). Guillain-Barre syndrome within 6 weeks of last tetanus vaccine. Bleeding disorders. Immunosuppression. Have epinephrine (1:1000) available. Elderly. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
May get suboptimal response with immunosuppressants (eg, chemotherapy, high dose corticosteroids ≥2 weeks, radiation); consider deferring. |
| Adverse Reactions |
|
Local reactions (eg, erythema, tenderness), headache, malaise, fever; rare: neurological disorders. |
| How Supplied |
|
Single-dose prefilled syringe (0.5mL)—10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
